Reproductive Biomedicine Online

Overview

This journal covers the formation, growth and differentiation of the human embryo. It is intended to bring to public attention new research on biological and clinical research on human reproduction and the human embryo including relevant studies on animals. It is published by a group of scientists and clinicians working in these fields of study, and independently of any publishing house. Its audience comprises researchers, clinicians, practitioners, academics and patients.

Web and paper versions of this journal bring up-to-date news on the clinical and scientific aspects of this topic, in two volumes per annum with a minimum of three issues per volume. New information, in the form of research papers and comment are presented in English, rapidly and responsibly, together with publishing-associated activities including articles, reviews, abstracts, editorials, commentaries, letters, opinions, case reports, patient information, conference reports, items relevant to counselling, interviews, ethics and law for patients, and other items. The journal is hyperlinked with websites of two charities covering pregnancy and miscarriage, and IVF and infertility.

Every attempt is made to publish rapidly and responsibly. Abstracts are posted on web soon after receipt, with a strong disclaimer stating that this material has not yet been peer-reviewed. Refereeing time is kept to a minimum, and full texts are presented on web immediately the refereeing and adjudicating process is ended. Fully proofed papers are subsequently published in web and paper versions. Submitted items including editorials, comment, news from wider sources, short communications, matters of legal, ethical and counselling importance will be placed on web as soon as possible after their arrival in the office and at the Editor’s discretion. The Editor reserves the right to publish certain papers on web that have been criticised by the referees.

The internet version of papers enables data about reproductive health to be made rapidly available to men and women worldwide. Conference proceedings and reports, as well as book chapters discussing matters relevant to the journal’s activities will be published. The journal headquarters are located in Cambridge. Articles can be sent to editors in the UK, Europe, India and the USA. Copyright is held by Reproductive Healthcare Ltd.
North America
Aileen Rivera North America
917-825-3954
mailto:a.rivera@elsevier.com

Traci Peppers North America
347-449-4997
t.peppers@elsevier.com

EMEA
Katy Parker EMEA
+44 (0) 7796 925011
k.parker@elsevier.com

Monika Giergielewicz EMEA
+44 (0) 7796 925011
m.giergielewicz@elsevier.com

APAC
Virginia Van Homrigh APAC
61 448 008159
v.vanhomrigh@elsevier.com

Global Print Circulation
Online Only
 Avg. Global Monthly Visits 28,089
 Avg. Global Monthly Unique Visitors 11,155
 Avg. Global Monthly Page Views 15,560
 Avg. Global eTOC Distribution 13,533

Affiliation
AAB College of Reproductive Biology (AAB-CRB) / Alpha (Scientists in Reproductive Medicine) / American College of Embryology (ACE) / The Global Chinese Association for Reproductive Medicine (GCARM) / International Society for Fallopian Tubes and Reproductive Surgery (ISFT-RS) / International Society for In Vitro Fertilization (ISIVF) / Mediterranean Society for Reproductive Medicine (MSRM) / Preimplantation Genetic Diagnosis International Society (PGDIS) / Turkish Society of Reproductive Medicine (TSRM)

Audience
obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine. Impact Factor in 2010: 2.285

Editor-in-Chief
Senior Editor: Jacques Cohen
Digital Specs

**Website**

<table>
<thead>
<tr>
<th>POSITIONS</th>
<th>AD</th>
<th>SIZE (PIXELS)</th>
<th>EXPANDABLE (PIXELS)</th>
<th>EXPANDABLE DIRECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top</td>
<td>Leaderboard</td>
<td>728 x 90</td>
<td>728 x 315</td>
<td>Down</td>
</tr>
<tr>
<td>Top</td>
<td>Mobile Leaderboard</td>
<td>300 x 50 or 320 x 50</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Side</td>
<td>MPU</td>
<td>300 x 250</td>
<td>600 x 250</td>
<td>Left</td>
</tr>
<tr>
<td>Side</td>
<td>Skyscraper</td>
<td>160 x 600 or 300 x 600</td>
<td>320 x 600</td>
<td>Left</td>
</tr>
<tr>
<td>On page load</td>
<td>Prestitial*</td>
<td>300 x 250 or 480 x 640</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

**FORMATS**
- jpeg, png, gif, HTML5†, 3rd party tags

**TRACKING PIXELS**
- Yes

**MAX FILE SIZE**
- 200 KB

**MAX ANIMATION (TIME/LOOPS)**
- 15 seconds/3 loops

**PRESTITIAL FREQUENCY**
- 1 impression/6hrs/user

*Supply iFRAME tags for scrolling elements in ad; HTML5 must be provided as a 3rd party tag for prestitial banners.

†Excluding personally identifiable information (PII).

**eTOC Email**

<table>
<thead>
<tr>
<th>POSITION</th>
<th>AD</th>
<th>SIZE (PIXELS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top</td>
<td>Leaderboard</td>
<td>728 x 90</td>
</tr>
<tr>
<td>Middle</td>
<td>MPU</td>
<td>300 x 250</td>
</tr>
</tbody>
</table>

**FORMATS**
- jpeg, png, gif, (static image only)

**TRACKING PIXELS**
- No

**MAX FILE SIZE**
- 200 KB

**AIP Email**

<table>
<thead>
<tr>
<th>POSITION</th>
<th>AD</th>
<th>SIZE (PIXELS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top</td>
<td>Leaderboard</td>
<td>728 x 90</td>
</tr>
<tr>
<td>Side</td>
<td>Skyscraper</td>
<td>160 x 600</td>
</tr>
<tr>
<td>Middle</td>
<td>MPU</td>
<td>300 x 250</td>
</tr>
</tbody>
</table>

**FORMATS**
- jpeg, png, gif, (static image only)

**TRACKING PIXELS**
- No

**MAX FILE SIZE**
- 200 KB

**Animation and expandable banners unavailable**

Contact your sales representative for all digital advertising rates and opportunities.
1. Applicability

This Agreement contains all the terms and conditions applicable to supply of products and services agreed upon by Elsevier and the Client. Any additional terms and conditions contained in any proposals, invoices or other documents issued to the Client by Elsevier, or in any communication from the Client, shall not modify these terms and conditions unless expressly agreed by Elsevier in writing. Any variation to the terms and conditions must be in writing, signed, and dated by an authorized representative of Elsevier. Nothing in this Agreement shall limit or exclude Elsevier’s liability for fraudulent misrepresentation. Where products are supplied to the Client, the Client’s third party supplier or software such risk may be subject to additional terms.

2. Offer and acceptance

(1) Unless otherwise agreed by Elsevier in writing, an offer for supply of a Product or Service is made by Elsevier when it issues a Quotation or quotation document to the Client. An offer for supply is deemed to be withdrawn if Elsevier rescinds the offer in writing within three business days of the Quotation or quotation document being issued.

(2) An offer for supply is deemed to be accepted when the Client gives Elsevier written acceptance of the offer within three business days of the Quotation or quotation document being issued. Any acceptance of an offer for supply made outside of the time period specified above shall be invalid and shall not bind Elsevier.

3. Execution and modification of the order

(1) The Client shall provide Elsevier with such reasonable instructions as Elsevier shall require to execute the order. Such instructions shall include, but not be limited to, the characteristics and type of Product and Service to be supplied. The Client shall provide Elsevier with such reasonable instructions as Elsevier shall require to execute the order. Such instructions shall include, but not be limited to, the characteristics and type of Product and Service to be supplied.

(2) If the Client wishes to modify or cancel the order, the Client shall give Elsevier written notice thereof in accordance with the notice periods set out in the Quotation or quotation document.

4. Price, taxes and currency

(1) The price of the Products and Services shall be the price stated in the Quotation or quotation document. The price shall be exclusive of any taxes, duties, or other charges that are required to be added to the price.

(2) Unless otherwise agreed by Elsevier in writing, the price shall be exclusive of any taxes, duties, or other charges that are required to be added to the price.

5. Loss of or damage to Products

(1) The Client shall not be liable for any loss or damage to the Products unless such loss or damage is caused by the Products being returned to the Client.

(2) The Client shall not be liable for any loss or damage to the Products unless such loss or damage is caused by the Products being returned to the Client.

6. Payment

(1) Payment for the Products and Services shall be made in accordance with the terms and conditions set out in the Quotation or quotation document. Any variation to any terms and conditions must be in writing, signed, and dated by an authorized representative of Elsevier. Nothing in this Agreement shall limit or exclude Elsevier’s liability for fraudulent misrepresentation. Where products are supplied to the Client, the Client’s third party supplier or software such risk may be subject to additional terms.

7. Performance

(1) Elsevier shall perform the Services in accordance with the terms and conditions set out in the Quotation or quotation document. Any variation to any terms and conditions must be in writing, signed, and dated by an authorized representative of Elsevier. Nothing in this Agreement shall limit or exclude Elsevier’s liability for fraudulent misrepresentation. Where products are supplied to the Client, the Client’s third party supplier or software such risk may be subject to additional terms.

8. Force majeure

(1) If either party is unable to perform or delay the performance of any of its obligations under this Agreement due to circumstances beyond its control which were not intentionally or recklessly caused by that party, and which the party took reasonable care to avoid, then that party shall be relieved from such obligations to the extent of such delay or non-performance.

(2) Neither party shall be liable for any failure or delay in performance under this Agreement if the failure or delay is caused by forces beyond either party’s reasonable control, including, but not limited to: acts of war or terrorism; governmental acts, laws, statutes, rules, orders, or regulations; strikes, lockouts, or other labor disputes; acts of nature; or any other event or circumstances beyond the reasonable control of such party.”